NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/23/2026 13:06
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization8,147.11 mln
Float135 mln
Earnings Date08/10/2026
EPS
2.86
Solid
P / E
19.04
Moderately valued
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
13.85
Highly suspicious
1-Year Forecast
48.00
Limited downside
Relative Strength
98
/ 100
Top performer
Business Description
TG Therapeutics is a US-based biopharmaceutical company that develops and sells treatments for diseases driven by abnormal B-cell activity. Its flagship product, BRIUMVI, is an approved therapy for adults living with relapsing forms of multiple sclerosis. The company also has several drugs in development, including treatments targeting multiple sclerosis and certain blood-related conditions, and works alongside a number of pharmaceutical partners across global markets.
